An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. [electronic resource]
Producer: 20071004Description: 3630-6 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Enzyme-Linked Immunosorbent Assay
- Female
- Granzymes -- drug effects
- Humans
- Interleukin-2 Receptor alpha Subunit -- blood
- Interleukins -- administration & dosage
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Perforin
- Pore Forming Cytotoxic Proteins -- drug effects
- Recombinant Proteins -- administration & dosage
- Interleukin-21
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.